-

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA. Management will participate in a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT.

Live and archived webcasts will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx

At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visit genedx.com and connect with us on LinkedIn, X, Facebook, and Instagram.

Contacts

Investor Relations Contact:
investors@GeneDx.com

Media Contact:
press@GeneDx.com

GeneDx

NASDAQ:WGS

Release Versions

Contacts

Investor Relations Contact:
investors@GeneDx.com

Media Contact:
press@GeneDx.com

More News From GeneDx

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance....

GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset...

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal anomalies are identified....
Back to Newsroom